• Home
  • » 
  • Reports
  • » 
  • Organ-based / Targeted Drug Delivery Dev...

Targeted Drug Delivery Devices Market

Organ-based / Targeted Drug Delivery Devices Market for Biologics by Device Type, Target Organ, Therapeutic Area, Target Indication and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages
    339

  • View Count
    12962

  • Buy Now

Example Insights

This image highlights the context of Targeted Drug Delivery Devices Market report. In order to address the existing concerns related to the administration of biologics, several innovator companies claim to be developing a range of patient-centric drug delivery devices, intended to improve therapeutic outcomes at relatively lower costs This image provides list of Targeted Drug Delivery Devices for Biologics. Several industry and non-industry players across the world, claim to be involved in the development of a variety of novel medical devices that facilitate the targeted delivery of biologics to different sites in the human body This image presents current market landscape of Targeted Drug Delivery Devices for Biologics. Majority of the devices being developed for targeted delivery of biologics are intended for the delivery of anti-cancer medication, including a number of gene therapies and cell-based interventions
This image highlights the promising therapeutic areas for Targeted Drug Delivery Devices. The rising interest of stakeholders in developing stem cell and gene therapies for treating neurological and cardiovascular disorders, can be validated from the growing research and development activity in this domain This image provides information about completed, ongoing and planned clinical studies of stem cell and gene therapies. Several clinical trials focused on evaluating the intra-organ delivery of various stem cell and gene therapies have been registered over the past few years, with studies being conducted across different geographical regions This image provides list of Stem Cell and Gene Therapy Developers. An assessment of existing stem cell and gene therapy developers revealed that North America is presently a hub for the development of advanced biologics, presenting substantial partnering opportunities for device developers
This image provides information on the current and future market trends and potential growth of Targeted Drug Delivery Devices Market for Biologics. The market for drug-device combination products is estimated to be worth over USD 3 billion by 2030; the projected opportunity is likely to be well distributed across key device types, target organs and therapeutic areas    

Report Description

Targeted Drug Delivery Devices Market Overview

The market for drug device combination products in the organ-based / targeted drug delivery devices for biologics market is expected to grow from around $30 million currently to $4,967 million by 2030. Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.   

In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order, no selection criteria) Advance® CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse® IL-12, SmartFlow® neuro ventricular cannula and MailPan®. Some of the aforementioned drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.  

Scope Of the Report

The ‘Organ-based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such medical devices, over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes: 

  • A detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulation based delivery device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.        
  • Elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.
  • An assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas.
  • A clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.
  • An analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company. 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market, for the time period 2020-2030. Our year-wise projections for the current and future opportunity have further been segmented on the basis of [A] type of device (encapsulation based delivery device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • William L Rust, Founder and Chief Executive Officer, Seraxis
  • Manuel Pires, Junior Business Developer, Defymed
  • R. Lyle Hood, Assistant Professor, University of Texas at San Antonio
  • Anonymous, Postdoctoral Associate, Massachusetts Institute of Technology  

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What type of devices are capable of providing targeted delivery of biologics?
  • Who are the leading device developers in this domain?
  • What are the key promising therapeutic areas for the development of targeted drug delivery devices for stem cell and gene therapies?
  • Which companies can be considered as potential strategic partners for device developers?
  • How is the current and future opportunity likely to be distributed across key market segments and geographical regions?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the medical devices that are capable of targeted delivery of biologics market in the mid to long-term.

Chapter 3 provides a general overview of drug delivery devices for biologics, focusing on the different routes of administration and the challenges associated with these delivery devices. The chapter also highlights the need for the development of targeted delivery devices for biologics. In addition, it presents the information on the different types of these targeted devices, the key advantages offered and a section on concluding remarks.

Chapter 4 provides a detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulation based delivery device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.

Chapter 5 features elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.

Chapter 6 features an elaborate assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas, since 2015.

Chapter 7 features a geographical clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.

Chapter 8 features an analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company.

Chapter 9 presents a comprehensive market forecast analysis, highlighting the likely growth of the targeted drug delivery devices market for biologics, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] type of device (encapsulation based delivery device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Chapter 10 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 11 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in this domain. In this study, we spoke to William L Rust (Founder and Chief Executive Officer, Seraxis),  Manuel Pires (Junior Business Developer, Defymed),  R. Lyle Hood (Assistant Professor, University of Texas at San Antonio) and Anonymous (Postdoctoral Associate, Massachusetts Institute of Technology)

Chapter 12 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report 
1.2. Research Methodology 
1.3. Key Questions Answered
1.4 Chapter Outlines 

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices for Biologics
3.3. Routes of Drug Administration
3.4. Challenges Associated with Drug Delivery of Biologics
3.5. Need for Targeted Drug Delivery

3.6. Devices for Targeted Delivery of Biologics
3.6.1. Types of Devices
3.6.2. Key Advantages

3.7. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Drug Delivery Devices for Biologics: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Target Organ
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Target Therapeutic Area
4.2.6. Analysis by Type of Biologic Delivered
4.2.7. Analysis by Type of Therapy Delivered
4.2.8. Analysis by Route of Administration
4.3. Targeted Drug Delivery Devices for Biologics: Additional Information
4.4. Targeted Drug Delivery Devices for Biologics: List of Developers
4.4.1. Analysis by Type of Stakeholder
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Location of Headquarters

5. DEVICE PROFILES
5.1. Chapter Overview
5.2. Alcyone MEMS Cannula (AMCTM)
5.2.1. Device Overview
5.2.2. Key Development Highlights
5.2.3. Key Clinical Trial Results

5.3. Bullfrog® Micro-Infusion Device
5.3.1. Device Overview
5.3.2. Key Development Highlights
5.3.3. Key Clinical Trial Results

5.4. HelixTM Biotherapeutic Delivery System
5.4.1. Device Overview
5.4.2. Key Development Highlights
5.4.3. Key Clinical Trial Results

5.5. Orbit Subretinal Delivery System
5.5.1. Device Overview
5.5.2. Key Development Highlights
5.5.3. Key Clinical Trial Results

5.6. SmartFlow® Neuro Ventricular Cannula
5.6.1. Device Overview
5.6.2. Key Development Highlights 
5.6.3. Key Clinical Trial Results

5.7. Renexus®
5.7.1. Device Overview
5.7.2. Key Development Highlights 
5.7.3. Key Clinical Trial Results

6. PROMISING THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Neurological Disorders
6.2.1. Stem Cell Therapies
6.2.1.1. Publication Analysis
6.2.1.1.1. Methodology
6.2.1.1.2. List of Publications
6.2.1.1.3. Analysis by Number of Publications

6.2.1.2. Grant Analysis
6.2.1.2.1. Methodology
6.2.1.2.2. List of Academic Grants
6.2.1.2.3. Analysis by Number of Grants
6.2.1.2.4. Analysis by Grant Amount

6.2.2. Gene Therapies
6.2.2.1. Publication Analysis
6.2.2.1.1. Methodology
6.2.2.1.2. List of Publications
6.2.2.1.3. Analysis by Number of Publications

6.2.2.2. Grant Analysis
6.2.2.2.1. Methodology
6.2.2.2.2. List of Academic Grants
6.2.2.2.3. Analysis by Number of Grants
6.2.2.2.4. Analysis by Grant Amount

6.3. Cardiovascular Disorders
6.3.1. Stem Cell Therapies
6.3.1.1. Publication Analysis
6.3.1.1.1. Methodology
6.3.1.1.2. List of Publications
6.3.1.1.3. Analysis by Number of Publications

6.3.1.2. Grant Analysis
6.3.1.2.1. Methodology
6.3.1.2.2. List of Academic Grants
6.3.1.2.3. Analysis by Number of Grants
6.3.1.2.4. Analysis by Grant Amount

6.3.2. Gene Therapies
6.3.2.1. Publication Analysis
6.3.2.1.1. Methodology
6.3.2.1.2. List of Publications
6.3.2.1.3. Analysis by Number of Publications

6.3.2.2. Grant Analysis
6.3.2.2.1. Methodology
6.3.2.2.2. List of Academic Grants
6.3.2.2.3. Analysis by Number of Grants
6.3.2.2.4. Analysis by Grant Amount

6.3. Summary of R&D Activity

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell and Gene Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Sponsor / Collaborator 
7.3.5. Analysis by Type of Therapy 
7.3.6. Analysis by Therapeutic Area
7.3.7. Analysis by Therapeutic Indication 
7.3.8. Analysis by Route of Administration
7.3.9. Analysis by Trial Status and Trial Phase
7.3.10. Most Active Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.12. Analysis by Geographical Location
7.3.13. Analysis by Geographical Location and Trial Phase
7.3.14. Analysis by Geographical Location and Trial Status
7.3.15. Analysis by Geographical Location and Therapeutic Area
7.3.16. Analysis by Patients Enrolled and Trial Registration Year
7.3.17. Analysis by Patients Enrolled and Trial Phase
7.3.18. Analysis by Patients Enrolled and Type of Therapy
7.3.19. Analysis by Patients Enrolled and Therapeutic Area
7.3.20. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.4. Stem Cell Therapies: Clinical Trial Analysis 
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Sponsor / Collaborator 
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Therapeutic Indication
7.4.7. Analysis by Route of Administration
7.4.8. Analysis by Trial Status and Trial Phase
7.4.9. Analysis by Geographical Location
7.4.10. Analysis by Geographical Location and Trial Phase
7.4.11. Analysis by Geographical Location and Trial Status
7.4.12. Analysis by Geographical Location and Therapeutic Area
7.4.13. Analysis by Patients Enrolled and Trial Registration Year
7.4.14. Analysis by Patients Enrolled and Trial Phase
7.4.15. Analysis by Patients Enrolled and Therapeutic Area
7.4.16. Analysis by Patients Enrolled, Trial Status and Geographical Location

7.5. Gene Therapies: Clinical Trial Analysis 
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Sponsor / Collaborator 
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Therapeutic Indication
7.5.7. Analysis by Route of Administration
7.5.8. Analysis by Trial Status and Trial Phase 
7.5.9. Analysis by Geographical Location
7.5.10. Analysis by Geographical Location and Trial Phase
7.5.11. Analysis by Geographical Location and Trial Status
7.5.12. Analysis by Geographical Location and Therapeutic Area
7.5.13. Analysis by Patients Enrolled and Trial Registration Year
7.5.14. Analysis by Patients Enrolled and Trial Phase
7.5.15. Analysis by Patients Enrolled and Therapeutic Area
7.5.16. Analysis by Patients Enrolled, Trial Status and Geographical Location

8. LIKELY PARTNER ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Stem Cell Therapy Developers: Likely Partners for Device Developers
8.3.1. Opportunities in North America
8.3.1.1. Most Likely Partners 
8.3.1.2. Likely Partners
8.3.1.3. Less Likely Partners 

8.3.2. Opportunities in Europe
8.3.2.1. Most Likely Partners 
8.3.2.2. Likely Partners 
8.3.2.3. Less Likely Partners

8.3.3. Opportunities in Asia-Pacific and Rest of the World
8.3.3.1. Most Likely Partners
8.3.3.2. Likely Partners 
8.3.3.3. Less Likely Partners

8.4. Gene Therapy Developers: Likely Partner for Device Developers
8.4.1. Opportunities in North America
8.4.1.1. Most Likely Partners 
8.4.1.2. Likely Partners
8.4.1.3. Less Likely Partners 

8.4.2. Opportunities in Europe
8.4.2.1. Most Likely Partners 
8.4.2.2. Likely Partners 
8.4.2.3. Less Likely Partners

8.4.3. Opportunities in Asia-Pacific and Rest of the World
8.4.3.1. Most Likely Partners
8.4.3.2. Likely Partners 
8.4.3.3. Less Likely Partners

9. MARKET FORECAST
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Targeted Drug Delivery Devices Market for Biologics, Till 2030
9.4. Targeted Drug Delivery Devices Market for Biologics: Individual Drug Device Combination Product Sales Forecasts
9.4.1. BCDA-01 and HelixTM Biotherapeutic Delivery System
9.4.1.1. Target Patient Population
9.4.1.2. Device Forecast by Number of units
9.4.1.3. Sales Forecast

9.4.2. BCDA-02 and HelixTM Biotherapeutic Delivery System
9.4.2.1. Target Patient Population
9.4.2.2. Device Forecast by Number of units
9.4.2.3. Sales Forecast

9.4.3. Renexus®
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. LYS-SAF302 and SmartFlow® Neuro Ventricular Cannula
9.4.4.1. Target Patient Population
9.4.4.2. Device Forecast by Number of units
9.4.4.3. Sales Forecast

9.4.5. Cell-in-a-Box®
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast

9.4.6. DNX-2401 and Alcyone's MEMS Cannula
9.4.6.1. Target Patient Population
9.4.6.2. Device Forecast by Number of units
9.4.6.3. Sales Forecast

9.4.7. EYS606 and Electro-Transfection Injection System
9.4.7.1. Target Patient Population
9.4.7.2. Device Forecast by Number of units
9.4.7.3. Sales Forecast

9.4.8. NTCELL®
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast

9.4.9. TAVO and ImmunoPulse® IL-12
9.4.9.1. Target Patient Population
9.4.9.2. Device Forecast by Number of units
9.4.9.3. Sales Forecast

9.4.10. VY-AADC02 and SmartFlow® Neuro Ventricular Cannula
9.4.10.1. Target Patient Population
9.4.10.2. Device Forecast by Number of units
9.4.10.3. Sales Forecast

9.5. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Device, Till 2030
9.6. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Organ, Till 2030
9.7. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Indication, Till 2030
9.8. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Therapeutic Area, Till 2030
9.9. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Therapy Delivered, Till 2030

9.10. Targeted Drug Delivery Devices Market for Biologics: Distribution by Key Geographical Regions, Till 2030
9.10.1. Targeted Drug Delivery Devices Market for Biologics in North America, Till 2030
9.10.2. Targeted Drug Delivery Devices Market for Biologics in Europe, Till 2030
9.10.3. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Till 2030

10. CONCLUDING REMARKS
10.1. Chapter Overview

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Seraxis
11.2.1. Company Snapshot
11.2.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer

11.3. Defymed
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Manuel Pires, Junior Business Developer

11.4. University of Texas at San Antonio
11.4.1. Organization Snapshot
11.4.2. Interview Transcript: R. Lyle Hood, Assistant Professor

11.5. Massachusetts Institute of Technology
11.5.1. Organization Snapshot
11.5.2. Interview Transcript: Anonymous, Postdoctoral Associate

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS 

List Of Figures

Figure 3.1 Drug Delivery Devices for Biologics
Figure 3.2 Routes of Drug Administration
Figure 4.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Figure 4.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Figure 4.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Figure 4.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Figure 4.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Figure 4.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Figure 4.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Figure 4.8 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development and Target Therapeutic Area
Figure 4.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Figure 4.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Figure 4.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Figure 4.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Figure 4.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Figure 4.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Figure 4.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Figure 6.1 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.2 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.3 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.4 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.5 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.6 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.7 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.8 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.9 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.10 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Figure 6.11 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.12 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.13 Emerging Focus Area
Figure 6.14 Summary of R&D Activity
Figure 7.1 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.3 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.4 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.5 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Figure 7.6 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.7 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Figure 7.8 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.9 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.10 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.11 Most Active Non-Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.12 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.13 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.14 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.15 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.16 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.17 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.18 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.19 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.20 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.21 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.22 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.23 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Figure 7.24 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.25 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.26 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.27 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.28 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.29 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.30 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.31 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.32 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.33 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.38 Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.39 Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.40 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 7.41 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.42 Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.43 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.44 Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.45 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.46 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.47 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.48 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.49 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.50 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.51 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.52 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1 Likely Partner Analysis: Distribution by Company Size and Location of Headquarters of Stem Cell Therapy Developers
Figure 8.2 Likely Partner Analysis: Distribution by Company Size and Location of Headquarters of Gene Therapy Developers
Figure 9.1. Targeted Drug Delivery Devices Market for Biologics, Till 2030 (USD Million)
Figure 9.2 Device Forecast: Helix Biotherapeutic Delivery System, Till 2030 (Number of Units)
Figure 9.3 BCDA-01 Sales Forecast, Till 2030 (USD Million)
Figure 9.4 Device Forecast: HelixTM Biotherapeutic Delivery System, Till 2030 (Number of Units)
Figure 9.5 BCDA-02 Sales Forecast, Till 2030 (USD Million)
Figure 9.6 Renexus® Sales Forecast, Till 2030 (USD Million)
Figure 9.7 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Till 2030 (Number of Units)
Figure 9.8 LYS-SAF302 Sales Forecast, Till 2030 (USD Million)
Figure 9.9 Cell-in-a-Box® Sales Forecast, Till 2030 (USD Million)
Figure 9.10 Device Forecast: Alcyone's MEMS Cannula, Till 2030 (Number of Units)
Figure 9.11 DNX-2401 Sales Forecast, Till 2030 (USD Million)
Figure 9.12 Device Forecast: Electro-Transfection Injection System, Till 2030 (Number of Units)
Figure 9.13 EYS606 Sales Forecast, Till 2030 (USD Million)
Figure 9.14 NTCELL® Sales Forecast, Till 2030 (USD Million)
Figure 9.15 Device Forecast: ImmunoPulse® IL-12, Till 2030 (Number of Units)
Figure 9.16 TAVO Sales Forecast, Till 2030 (USD Million)
Figure 9.17 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Till 2030 (Number of Units)
Figure 9.18 VY-AADC02 Sales Forecast, Till 2030 (USD Million)
Figure 9.19 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Type of Device (USD Million)
Figure 9.20 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Organ (USD Million)
Figure 9.21 Targeted Drug Delivery Devices Market for Biologics: Market Attractiveness Analysis by Target Organ, 2026-2030
Figure 9.22. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Indication (USD Million)
Figure 9.23. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Target Therapeutic Area (USD Million)
Figure 9.24. Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Type of Therapy Delivered (USD Million)
Figure 9.25 Targeted Drug Delivery Devices Market for Biologics, Till 2030: Distribution by Key Geographical Region (USD Million)
Figure 9.26. Targeted Drug Delivery Devices Market for Biologics in North America, Till 2030 (USD Million)
Figure 9.27. Targeted Drug Delivery Devices Market for Biologics in Europe, Till 2030 (USD Million)
Figure 9.28. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Till 2030 (USD Million)
Figure 10.1. Concluding Remarks: Current Market Landscape Summary
Figure 10.2. Concluding Remarks: Clinical Trial Analysis
Figure 10.3. Concluding Remarks: Likely Partner Analysis
Figure 10.4. Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Targeted Drug Delivery Devices for Biologics: List of Approved / Under Development Devices
Table 4.2 Targeted Drug Delivery Devices for Biologics: Information on Type of Biologic Delivered, Type of Therapy Delivered and Route of Administration
Table 4.3 Targeted Drug Delivery Devices for Biologics: Additional Information
Table 4.4 Targeted Drug Delivery Devices for Biologics: List of Developers
Table 5.1 Targeted Drug Delivery Devices for Biologics: List of Devices Profiled
Table 5.2 Alcyone MEMS Cannula (AMCTM): List / Details of Clinical Trials
Table 5.3 Bullfrog® Micro-Infusion Device: List / Details of Clinical Trials
Table 5.4 HelixTM Biotherapeutic Delivery System: List / Details of Clinical Trials
Table 5.5 Orbit Subretinal Delivery System: List / Details of Clinical Trials
Table 5.6 SmartFlow® Neuro Ventricular Cannula: List / Details of Clinical Trials
Table 5.7 Renexus®: List / Details of Clinical Trials
Table 6.1 Stem Cell Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.2 Stem Cell Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.3 Stem Cell Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.4 Gene Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 6.5 Gene Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.6 Gene Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.7 Stem Cell Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.8 Stem Cell Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.9 Stem Cell Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 6.10 Gene Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 6.11 Gene Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.12 Gene Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 8.1 Stem Cell Therapy Developers in North America: Most Likely Partners
Table 8.2 Stem Cell Therapy Developers in North America: Likely Partners
Table 8.3 Stem Cell Therapy Developers in North America: Less Likely Partners
Table 8.4 Stem Cell Therapy Developers in Europe: Most Likely Partners
Table 8.5 Stem Cell Therapy Developers in Europe: Likely Partners
Table 8.6 Stem Cell Therapy Developers in Europe: Less Likely Partners
Table 8.7 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Most Likely Partners
Table 8.8 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Likely Partners
Table 8.9 Stem Cell Therapy Developers in Asia-Pacific and Rest of the World: Less Likely Partners
Table 8.10 Gene Therapy Developers in North America: Most Likely Partners
Table 8.11 Gene Therapy Developers in North America: Likely Partners
Table 8.12 Gene Therapy Developers in North America: Less Likely Partners
Table 8.13 Gene Therapy Developers in Europe: Most Likely Partners
Table 8.14 Gene Therapy Developers in Europe: Likely Partners
Table 8.15 Gene Therapy Developers in Europe: Less Likely Partners
Table 8.16 Gene Therapy Developers in Asia-Pacific and Rest of the World: Most Likely Partners
Table 8.17 Gene Therapy Developers in Asia-Pacific and Rest of the World: Likely Partners
Table 8.18 Gene Therapy Developers in Asia-Pacific and Rest of the World: Less Likely Partners
Table 9.1 Targeted Drug Delivery Devices Market for Biologics: List of Forecasted Candidates
Table 9.2 BCDA-01: Target Patient Population
Table 9.3 BCDA-02: Target Patient Population
Table 9.4 Renexus®: Target Patient Population
Table 9.5 LYS-SAF302: Target Patient Population
Table 9.6 Cell-in-a-Box®: Target Patient Population
Table 9.7 DNX-2401: Target Patient Population
Table 9.8 EYS606: Target Patient Population
Table 9.9 NTCELL®: Target Patient Population
Table 9.10 TAVO: Target Patient Population
Table 9.11 VY-AADC02: Target Patient Population
Table 10.1 Targeted Drug Delivery Devices Market for Biologics: Key Takeaways
Table 11.1 Seraxis: Key Highlights
Table 11.2 Defymed: Key Highlights
Table 11.3 University of Texas at San Antonio: Key Highlights
Table 11.4 Massachusetts Institute of Technology: Key Highlights
Table 12.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Table 12.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Table 12.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Table 12.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Table 12.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Table 12.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Table 12.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Table 12.8 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development and Target Therapeutic Area
Table 12.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Table 12.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Table 12.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Table 12.12 Device Developers: Distribution by Type of Stakeholder
Table 12.13 Device Developers: Distribution by Year of Establishment
Table 12.14 Device Developers: Distribution by Company Size
Table 12.15 Device Developers (Industry Players): Distribution by Location of Headquarters
Table 12.16 Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Table 12.17 Stem Cell Therapy for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.18 Stem Cell Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.19 Stem Cell Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.20 Gene Therapy for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.21 Gene Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.22 Gene Therapy for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.23 Stem Cell Therapy for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.24 Stem Cell Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.25 Stem Cell Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.26 Gene Therapy for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2019
Table 12.27 Gene Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Trend by Year, 2015-2020
Table 12.28 Gene Therapy for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.29 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.30 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.31 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.32 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.33 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Table 12.34 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.35 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.36 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.37 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.38 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.39 Most Active Non-Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.40 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.41 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.42 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.43 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.44 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.45 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.46 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.47 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.48 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.49 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Table 12.50 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Table 12.51 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.52 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.53 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.54 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Table 12.55 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.56 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Table 12.57 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.58 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.59 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.60 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.61 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.62 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.63 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.64 Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.65 Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.66 Gene Therapy Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 12.67 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.68 Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.69 Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.70 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.71 Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.72 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.73 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.74 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.75 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.76 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.77 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.78 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.79 Device Forecast: HelixTM Biotherapeutic Delivery System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.80 BCDA-01 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.81 Device Forecast: HelixTM Biotherapeutic Delivery System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.82 BCDA-02 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.83 Renexus® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.84 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.85 LYS-SAF302 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.86 Cell-in-a-Box® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.87 Device Forecast: Alcyone's MEMS Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.88 DNX-2401 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.89 Device Forecast: Electro-Transfection Injection System, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.90 EYS606 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.91 NTCELL® Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.92 Device Forecast: ImmunoPulse® IL-12, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.93 TAVO Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.94 Device Forecast: SmartFlow® Neuro Ventricular Cannula, Conservative, Base and Optimistic Scenarios, Till 2030 (Number of Units)
Table 12.95 VY-AADC02 Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.96 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Type of Device, (USD Million)
Table 12.97 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Organ, (USD Million)
Table 12.98 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Indication, (USD Million)
Table 12.99 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Target Therapeutic Area, (USD Million)
Table 12.100 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Type of Therapy Delivered, (USD Million)
Table 12.101 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2030: Distribution by Key Geographical Regions, 2025 and 2030
Table 12.102 Targeted Drug Delivery Devices Market for Biologics in North America, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.103 Targeted Drug Delivery Devices Market for Biologics in Europe, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)
Table 12.104 Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2030 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 4D Molecular Therapeutics
  2. AbbVie
  3. Abeona Therapeutics 
  4. Advanced Catheter Therapies
  5. Advanced Materials and BioEngineering Research
  6. Advantagene
  7. Advaxis
  8. Adverum Biotechnologies
  9. Alcyone Lifesciences
  10. Allergan
  11. AlphaVax
  12. Altaco XXI
  13. Alvimedica
  14. American Gene Technologies International
  15. Amgen
  16. Amicus Therapeutics
  17. Anaeropharma Science
  18. Anchiano Therapeutics
  19. AnGes
  20. Angionetics
  21. Anhui Medical University
  22. apceth Biopharma
  23. Apic Bio
  24. Applied Genetic Technologies Corporation
  25. AskBio
  26. Astellas Pharma
  27. Athersys
  28. Atrium Medical
  29. Austrianova
  30. AveXis
  31. Axis Biotec Brasil
  32. Axovant
  33. Azidus Brasil
  34. BHI Therapeutic Sciences
  35. BioCardia
  36. Biogen
  37. BioGenCell
  38. BioInvent
  39. Bioquark
  40. BioRestorative Therapies
  41. Biosense Webster
  42. Biosensors International
  43. BIOTRONIK
  44. bluebird bio
  45. Boehringer Ingelheim
  46. Bone Therapeutics
  47. Boston Scientific
  48. Boston TransTec
  49. BrainStorm Cell Therapeutics
  50. Bristol-Myers Squibb
  51. Bukwang Pharmaceutical
  52. Caladrius Biosciences
  53. California Institute for Regenerative Medicine
  54. Capricor Therapeutics
  55. CAR-T (Shanghai) Biotechnology 
  56. Case Western Reserve University
  57. Celixir
  58. CellProthera
  59. Celsion
  60. Celyad
  61. Cesca Therapeutics
  62. CHA Biotech
  63. Children's Hospital of Chongqing Medical University
  64. Chonbuk National University
  65. ClearPoint Neuro
  66. Clinica Universidad de Navarra
  67. Cold Genesys
  68. CombiGene
  69. Cook Regentec
  70. Copernicus Therapeutics
  71. Corestem
  72. Cornell University
  73. CRISPR Therapeutics
  74. Cynvec
  75. Cytopeutics
  76. Daegu Gyeongbuk Institute of Science & Technology
  77. Defymed
  78. DiscGenics
  79. DNAlite Therapeutics
  80. DNAtrix
  81. Duke University
  82. EdiGene
  83. Editas Medicine
  84. Eisai
  85. Endsulin
  86. Epeius Biotechnologies
  87. Ever Supreme Bio Technology
  88. Eyevensys
  89. Ferrer Internacional
  90. FKD Therapies
  91. Flowonix Medical
  92. Gemini Therapeutics
  93. Genelux
  94. Genenta Science
  95. Genentech
  96. Generation Bio
  97. Genexine
  98. Genprex
  99. GenSight Biologics
  100. Global Cell Med
  101. Gloriana Therapeutics
  102. Gradalis
  103. Gwo Xi Stem Cell
  104. Gyroscope Therapeutics
  105. Harvard University
  106. Hebei Newtherapy BIo-Pharma Technology
  107. Hefei University of Technology
  108. Hemera Biosciences
  109. Hemostemix
  110. Hitachi Chemical
  111. Homology Medicines
  112. Hope Biosciences
  113. HORAMA
  114. Houston Methodist Research Institute
  115. Inovio Pharmaceuticals
  116. Institute of Robotic and Intelligent Systems
  117. IVERIC bio
  118. Janssen
  119. Japan Regenerative Medicine
  120. Japan Tissue Engineering
  121. jCyte
  122. Jennerex Biotherapeutics
  123. Juventas Therapeutics
  124. Kadimastem
  125. Karolinska Institutet
  126. Kolon TissueGene
  127. Korea Advanced Institute of Science and Technology
  128. K-Stem Cell
  129. Kubota Pharmaceutical
  130. Lacerta Therapeutics
  131. Lifecells
  132. Lineage Cell Therapeutics
  133. Living Cell Technologies
  134. Lokon Pharma
  135. Longeveron
  136. Lysogene
  137. Marsala Biotech
  138. Massachusetts Institute of Technology
  139. Med Cell Bahamas
  140. MedImmune
  141. MEDIPOST
  142. Medtronic
  143. MeiraGTx
  144. Mercator MedSystems
  145. Merck
  146. Meridigen Biotech
  147. Merit Medical Systems
  148. Mesoblast
  149. Michael J. Fox Foundation
  150. Momotaro-Gene
  151. MultiVir
  152. Nano Therapeutics
  153. NanoCor Therapeutics
  154. National Cancer Institute (NCI)
  155. National University of Ireland, Galway (NUI Galway)
  156. Nature Cell
  157. Neuracle Genetics
  158. Neuralgene
  159. Neurocrine Biosciences
  160. Neurogene
  161. NeuroGeneration
  162. Neurotech Pharmaceuticals
  163. NextCell Pharma
  164. Nightstar Therapeutics
  165. Nipro
  166. Noray Biosciences Group
  167. Novadip Biosciences 
  168. Novartis
  169. Novo Nordisk
  170. NuVasive
  171. Ocugen
  172. Oncolys BioPharma
  173. Oncos Therapeutics
  174. OncoSec Medical
  175. Orbit Biomedical
  176. ORCA Therapeutics
  177. Oxford BioMedica
  178. Passage Bio
  179. Pattern BioScience
  180. PeriphaGen
  181. Pfizer
  182. PharmaCyte Biotech
  183. Pharmicell
  184. Pluristem Therapeutics
  185. Plus Therapeutics
  186. Prevail Therapeutics
  187. Promethera Biosciences
  188. PsiOxus Therapeutics
  189. PTC Therapeutics
  190. Purdue University
  191. Q Therapeutics
  192. Regeneron Pharmaceuticals
  193. REGENXBIO
  194. Reliance Life Sciences
  195. ReNeuron 
  196. Renishaw
  197. Renova Therapeutics
  198. Riordan Technologies
  199. Roche
  200. ROHTO Pharmaceutical
  201. Royal College of Surgeons in Ireland
  202. SanBio
  203. Sangamo Therapeutics
  204. Sanofi
  205. Sarepta Therapeutics
  206. Scancell
  207. Sclnow Biotechnology 
  208. SCM LifeScience
  209. Seneca Biopharma
  210. Sentien Biotechnologies
  211. Seraxis
  212. Shandong Qilu Stem Cells Engineering
  213. Shanghai East Hospital
  214. Shanghai Sunway Biotech
  215. Shenzhen Hornetcorn Biotechnology
  216. Shire
  217. Sibiono GeneTech
  218. Sigilon Therapeutics
  219. Silenseed
  220. SillaJen
  221. Smartwise
  222. SOTIO
  223. Southwest Research Institute
  224. Spark Therapeutics
  225. Stanford University
  226. Stem Med
  227. Stemedica Cell Technologies
  228. Steminent Biotherapeutics
  229. Stempeutics Research
  230. StrideBio
  231. Surmodics
  232. SWIB Holding
  233. Taiwan Bio Therapeutics
  234. Takeda
  235. Targovax
  236. TARIS Biomedical
  237. Taxus Cardium Pharmaceuticals
  238. Teleflex
  239. Tenaya Therapeutics
  240. The Emmes Company
  241. The Second People’s Hospital of Hefei
  242. TheraBiologics
  243. Theravectys
  244. ThermopeutiX
  245. Tianhe Stem Cell Biotechnologies
  246. Tianjin Weikai Biological Engineering
  247. TICEBA
  248. Tocagen
  249. Transgene
  250. Translational Research Institute
  251. TransVascular
  252. Tricumed
  253. Trinity College Dublin
  254. U.S. Stem Cell
  255. Ultragenyx Pharmaceutical
  256. uniQure
  257. United Therapeutics
  258. University of Colorado
  259. University of Michigan
  260. University of Milan
  261. University of Minnesota Medical School
  262. University of Pennsylvania
  263. University of Texas
  264. University of Washington
  265. VBL Therapeutics
  266. VcanBio Center for Translational Biotechnology
  267. VCN Biosciences
  268. Vericel
  269. Verve Therapeutics
  270. Vessl
  271. ViroMed
  272. Virttu Biologics
  273. Viscofan BioEngineering
  274. Voyager Therapeutics 
  275. XyloCor Therapeutics
  276. Ziopharm Oncology

Source: www.cancer.org/latest-news/facts-and-figures-2020.html

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.